Alpha Teknova, Inc. (TKNO)
TKNONASDAQ-GMBiotechnology: In Vitro & In Vivo Diagnostic Substances
$8.62
-0.1100 (-1.26%) today
Closed, Nov 11, 4:00 PM ET
- Market cap
- $542.22m
- P/E
- –
- EPS, last 4 quarters
- $-0.2900
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.91 to $9.48
- Average volume
- –
- Previous close
- $8.73
Analysts
7 coveringBuy6 buy, 1 hold, 0 sell
Targets a year out average $10.00, +16.0% from here
Earnings
next estimate $-0.0700Next report
Dec 2025
0.0%
Mar 2026
–
Jun 2026
+25.0%
Sep 2026
0.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $9.98m | $11.08m | $12.19m | $12.70m |
| Gross profit | $3.24m | $3.78m | $4.88m | $4.83m |
| Operating income | -$4.61m | -$4.30m | -$2.89m | -$3.21m |
| Net income | -$4.76m | -$4.55m | -$3.17m | -$3.49m |
Last four quarters: revenue $45.95m, margin -34.8%, free cash flow -$6.38m
News
8 latest- Alpha Teknova (TKNO) Q3 2026 Earnings Call TranscriptThe Motley Fool · 7 days ago
- Alpha Teknova Q3 Earnings Call HighlightsMarketBeat · 7 days ago
- Alpha Teknova, Inc. Reports Third Quarter 2026 Revenue of $12.7 million and Raises Revenue Guidance to $46-48 millionFintel · Nov 5, 2026
- Alpha Teknova (TKNO) Reports Q3 Loss, Tops Revenue EstimatesZacks · Nov 4, 2026
- Alpha Teknova Consensus Price Target Raised by 19.05% to $10.93Fintel · Oct 23, 2026
- Alpha Teknova (TKNO) Stock Jumps 5.1%: Will It Continue to Soar?Zacks · Oct 23, 2026
- Alpha Teknova, Inc. Enters Underwriting Agreement for 8,000,000 Share Public Offering and Announces Preliminary Financial Estimates for the Three Months Ended September 30, 2026Fintel · Oct 22, 2026
- Teknova Prices $40 Mln Public Offering At $5 Per Share RTTNews · Oct 20, 2026
The company
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel breakthroughs that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in genomics, molecular diagnostics, and emerging therapeutic modalities. Our fast turnaround of high-quality agar plates, microbial culture and cryopreservation media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 180,000 square feet of state-of-the-art facilities, Teknova's modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of next-generation therapies.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- teknova.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.